KeywordsT315; acute myeloid leukemia; apoptosis; autophagy; autophagic cell death; acute myeloid leukaemia (AML); AZA-AML-001 trial; Austrian Azacitidine Registry (AAR); real-world data; azacitidine; acute erythroleukemia; azacitidine; decitabine; Flt3; growth factor receptors; cytokines; HSC; hematopoiesis; leukemia; Flt3; hematopoiesis; acute myeloid leukemia (AML); cytokines; Flt3 with internal tandem duplications (FLT3-ITD); blood cells; vitamin D receptor; retinoic acid receptors; expression; CYP24A1; CYP26A1; differentiation; hematopoietic stem cells; acute myeloid leukaemia; EZH2; mass spectrometry; methylation; eEF1A1; acute myeloid leukemia; t(4; 15)(q31; q22); TMEM154-RASGRF1; ATRA; retinoid; NCT02273102; RUNX1; mutations; acute myeloid leukemia; hypomethylating agents; chemotherapy; prognosis; acute myeloid leukemia; immunotherapy, monoclonal antibodies; hypomethylating agents; microenvironment; NF-κB; Nrf2; EF-24-GSH adduct; EF-24-NAC adduct; K562 cells; n/a
